Persistence of earlier HIV-1 drug resistance mutations at new treatment failure

Journal of Medical Virology

Volumn 68, Issue 4, 2002, Pages 473-478

  Svedhem, Veronica ^a   Lindkvist, Annica ^a   Lidman, Knut ^a   Sönnerborg, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antiretroviral drugs; Mutations; NNRTI; NRTI; Persistence; Protease inhibitor

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; THYMIDINE DERIVATIVE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CROSS RESISTANCE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERSISTENT VIRUS INFECTION; SWEDEN; TREATMENT FAILURE; VIRUS MUTATION; VIRUS STRAIN;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; VIRAL PROTEINS; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036883493     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10246     Document Type: Article

References (25)

1. Birk M, Svedhem V, Sonnerborg A. 2001. Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy. AIDS 15:1359-1368.
2. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D. 1997. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 71:1089-1096.
3. Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M, Volberding PA. 1999. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 179:1375-1381.
4. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344:520-522.
5. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L, Mellors J. 2000. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 5: 41-48.
6. Feinberg M. 1997. Hidden dangers of incompletely suppressive antiretroviral therapy. Lancet 349:1408-1409.
7. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337:734-739.
8. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
9. Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, Puel J, Massip P. 1999. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine. J Med Virol 59:507-511.
10. Karlsson AC, Lindkvist A, Lindbäck S, Gaines H, Sönnerborg A. 2001. Recent origen of HIV-1 quasispecies in resting memory CD4+ T-lymphocytes in untreated and suboptimally treated patients. J Infect Dis 184:1392-1401.
11. Larder BA, Bloor S. 2001. Analysis of clinical isolates and site-directed mutants reveals the genetic determinants of didanosine resistance. Fifth International Workshop on HIV Drug Resistance and Treatment Strategies.
12. Lucas GM, Chaisson RE, Moor RD. 1999. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 131:81-87.
13. Miller V, Sturmer M, Staszewski S, Groschel B, Hertogs K, de Bethune MP, Pauwels R, Harrigan PR, Bloor S, Kemp SD, Larder BA. 1998. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS 12:705-712.
14. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher CA. 1999. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13:2349-2359.
15. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860.
16. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. 2000. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133:21-30.
17. Pellegrin I, Garrigue I, Caumont A, Pellegrin JL, Merel P, Schrive MH, Bonot P, Fleury H. 2001. Persistence of zidovudine-resistance mutations in HIV-1 isolates from patients removed from zidovudine therapy for at least 3 years and switched to a stavudine-containing regimen. AIDS 15:1071-1073.
18. Preston BD, Poiesz BJ, Loeb LA. 1988. Fidelity of HIV-1 reverse transcriptase. Science 242:1168-1171.
19. Ross L, Henry K, Paar D, Salvato P, Shaefer M, Fisher R, Liao Q, St Clair M. 2001. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudineexperienced subjects with viremia after treatment with stavudine-containing regimens. J Hum Virol 4:217-222.
20. Sharma PL, Crumpacker CS. 1997. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J Virol 71:8846-8851.
21. Shulman NS, Machekano RA, Shafer RW, Winters MA, Zolopa AR, Liou SH, Hughes M, Katzenstein DA. 2001. Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy. J Acquir Immune Defic Syndr 27:377-380.
22. Tisdale M, Alnadaf T, Cousens D. 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 41:1094-1098.
23. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
24. Winters MA, Schapiro JM, Lawrence J. 1997. Genotypic and phenotypic analysis of the protease gene in HIV-1-infected patients that failed long-term saquinavir therapy and switched to other protease inhibitors. Antiviral Ther 2:25-26.
25. Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC, Efron B. 1999. HIV-1 genotypic resistance patterns predict response to saquinavir- ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med 131:813-821.